Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Tricia Elliott MD, FAAFP
Tricia C. Elliott MD, FAAFP Associate Editor
David Rakel MD, FAAFP
David Rakel MD, FAAFP Editor-in-Chief
Jonathan Temte MD, PhD
Jonathan Temte MD, PhD Advisory Board
See All Experts
story of the week
Published in Primary Care and
1 other channel

Journal Scan / Research · August 24, 2020

Cost-Effectiveness of Sacubitril–Valsartan in Hospitalized Patients Who Have HFrEF

JAMA Cardiology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Peter Lin MD, CCFP

JAMA Cardiology
Cost-Effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction
JAMA Cardiol 2020 Aug 12;[EPub Ahead of Print], TA Gaziano, GC Fonarow, EJ Velazquez, DA Morrow, E Braunwald, SD Solomon

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Recently Updated